Over the next five years, biosimilar copycats will hammer away at blockbuster medicines from pharmaceutical companies like AbbVie, Roche and the Dow's Johnson & Johnson, experts say.

source https://finance.yahoo.com/m/40f4e257-99ac-3e60-95eb-8dbd2f1f84c5/can-copycats-take-on-%24198.html?.tsrc=rss